Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $21 from $19 and keeps an Equal Weight rating on the shares after the company provided its Q4 update. A BLA submission for obexelimab in IgG4-RD is expected in Q2 and an MAA submission in the second half, the analyst noted.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
- Zenas BioPharma price target lowered to $41 from $43 at Citi
- IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
- Morning Movers: National Storage surges following Public Storage buyout
- Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year